Product name:
siFalin-TATE/ siTATE
Chemical precursor for radiopharmaceutical preparations with [18F]
Molecular Weight:
2160.9 [g/mol] (m.i.),
2162.5 [g/mol] (av.)
Molecular Formula:
C98H141N18O30S2SiF
*Delivery time: On stock
General Information
| Product no.: | 50139 |
| Product name: | siFAlin-TATE, siTATE |
| Sequence: | SiFAlin-Aoa-Asn(AcNH-β-Glc)-Asp2-PEG-Tyr³-octreotate |
| Molecular weight: | 2160.9 [g/mol] (m.i.), 2162.5 [g/mol] (av.) |
| Molecular formula: | C98H141N18O30S2SiF |
| CAS no.: | n.a. |
Product description
Chemical precursor with SiFA (silicone-fluoride acceptor) for radiopharmaceutical preparations with [18F] in high radiochemical yields. siTATE allows imaging of somatostatin receptors, e.g. for the identification of neuroendocrine tumors.
For use by qualified personnel only.
For research use only.
Quantity
Product no. 50139: 150nmol± 10% (TFA salt)
Packaging
Clear tubular glass vials type I (borosilicate, 2 mL) with lyophilisation stoppers and closed with aluminium caps.
Storage and Stability
Storage at -20°C (± 5°C), sealed, away from moisture and protected from light.
Certificates
Certificate of Quality
Literature
[1] Gower-Fry, L. et al. (2021) Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals, Pharmaceuticals 2021, 14, 701
[2] Lindner S. et al. (2020) Automated production of [18F]SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors, Nuclear Medicine and Biology, 2020, 88–89 (2020) 86–95
[3] Lindner S. et al. (2020) Radiosynthesis of [18F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography, Nature protocols, 2020, https://doi.org/10.1038/s41596-020-00407-y
[4] Ilhan H. et al. (2019) Biodistribution and first clinical results of 18F-SiFAlin-TATE PET a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors, Eur. J. Nucl. Med. Mol. Imaging, 2019, 47, 870–880 (2020)
